pneumonia
common
ill
estim
approxim
million
case
per
year
accord
world
health
organ
lower
respiratori
tract
infect
account
approxim
death
per
year
worldwid
virus
common
caus
communityacquir
pneumonia
particularli
among
children
among
pediatr
communityacquir
pneumonia
studi
viral
caus
specif
sought
incid
viral
etiolog
infect
common
virus
isol
respiratori
syncyti
viru
rsv
influenza
viru
parainfluenza
viru
adenoviru
canadian
studi
found
among
adult
disclosur
author
noth
disclos
satur
highlevel
oxygen
radiograph
characterist
lack
chf
would
fit
descript
acut
respiratori
distress
syndrom
ard
secondari
viral
pneumonia
seen
pandem
mani
believ
much
excess
mortal
attribut
influenza
epidem
relat
secondari
bacteri
pneumonia
organ
staphylococcu
aureu
streptococcu
pneumonia
opinion
support
autopsi
studi
report
sever
bronchopneumonia
ardslik
ill
cultur
bacteria
associ
pneumon
lesion
howev
case
evid
bacteri
pneumonia
good
epidemiolog
evid
support
emerg
antigen
novel
influenza
viru
high
virul
mani
younger
peopl
never
expos
like
signific
contributor
high
mortal
rate
younger
age
group
addit
complic
sever
respiratori
failur
influenza
infect
associ
central
nervou
system
cardiac
skelet
renal
hepat
complic
spring
outbreak
attribut
new
viral
pathogen
swineorigin
influenza
led
signific
number
case
sever
hypoxem
respiratori
failur
attribut
viral
pneumonia
outbreak
began
southwestern
unit
state
mexico
rapid
spread
throughout
rest
unit
state
canada
rest
world
spread
led
world
health
organ
declar
global
pandem
alert
june
number
patient
requir
admiss
icu
viral
pneumon
caus
infect
much
larger
rate
due
season
influenza
increas
incid
critic
ill
along
high
transmiss
rate
rapid
increas
case
number
short
period
time
creat
signific
stress
hospit
resourc
sever
countri
particularli
term
icu
resourc
need
invas
ventilatori
support
rel
underresourc
nation
western
hemispher
reportedli
exceed
icu
capac
farmer
c
person
commun
sinc
onset
pandem
march
countri
commun
report
case
pandem
influenza
death
australian
provinc
approxim
popul
develop
ill
infect
patient
hospit
hospit
patient
requir
icu
care
similar
proport
report
public
health
agenc
canada
pandem
argentina
case
influenzalik
ill
admit
hospit
die
januari
unit
kingdom
patient
adult
children
admit
either
icu
highdepend
unit
mortal
rate
die
previous
healthi
hospit
mortal
rate
increas
increas
age
overal
casefat
rate
low
lower
gener
report
season
influenza
although
much
variabl
estim
viral
epidem
initi
suspect
increas
number
young
patient
mexico
hospit
sever
infrequ
fatal
pneumonia
report
seri
initi
case
sever
pneumonia
mexico
chowel
colleagu
found
death
case
sever
pneumonia
occur
patient
age
year
repres
signific
shift
age
distribut
patient
sever
diseas
death
season
influenza
australia
new
zealand
patient
admit
icu
within
period
time
confirm
mean
number
admiss
viral
pneumon
within
period
prior
year
despit
young
age
patient
requir
icu
admiss
respiratori
failur
highest
death
rate
among
older
year
howev
comparison
season
influenza
affect
younger
individu
number
year
life
lost
substanti
estim
year
unit
state
may
decemb
among
requir
critic
care
canada
femal
mean
age
year
major
patient
least
comorbid
commonli
chronic
lung
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
bronchopulmonari
dysplasia
obes
hypertens
smoke
diabet
howev
major
kind
major
chronic
organ
failur
typic
patient
admit
medic
icu
mean
acut
physiolog
chronic
health
evalu
ii
apach
ii
score
icu
patient
major
comorbid
present
similar
patient
demograph
note
countri
mani
known
risk
factor
influenza
infect
indigen
person
australia
new
zealand
well
aborigin
canadian
overrepres
among
critic
ill
obes
interestingli
previous
link
complic
influenza
promin
risk
factor
sever
respiratori
diseas
secondari
pregnanc
well
describ
risk
factor
complic
season
influenza
howev
number
critic
ill
pregnant
women
pneumon
disproportion
larg
led
excess
mortal
group
australia
new
zealand
pregnant
women
rel
risk
requir
icu
admiss
ill
comparison
nonpregn
women
childbear
age
sixtynin
percent
women
requir
mechan
ventil
die
viral
pneumon
ard
california
pregnant
women
infect
requir
icu
admiss
die
lead
influenzaspecif
matern
mortal
rate
per
live
birth
final
factor
associ
treatment
shown
correl
sever
diseas
canadian
data
show
interv
onset
symptom
initi
antivir
therapi
hospit
longer
among
patient
sever
diseas
icu
admiss
death
also
shown
true
among
hospit
patient
unit
state
observ
studi
sever
influenza
pneumonia
suggest
earli
initi
antivir
therapi
associ
improv
outcom
although
case
mild
selflimit
signific
number
case
sever
hypoxem
respiratori
failur
five
clinic
present
commonli
note
viral
pneumon
exacerb
asthma
copd
exacerb
underli
diseas
ie
chf
chronic
renal
diseas
secondari
bacteri
pneumonia
croupbronchiol
pediatr
popul
clinic
present
frequent
requir
icu
admiss
viral
pneumon
patient
present
rapidli
progress
refractori
hypoxemia
bilater
alveolar
infiltr
cxr
patient
fulfil
criteria
acut
lung
injuri
ali
ard
patient
viral
pneumon
hypoxem
respiratori
failur
present
symptom
cough
dyspnea
fever
patient
rapidli
progress
hypoxemia
high
ventilatori
demand
case
seri
greater
patient
admit
icu
syndrom
requir
mechan
ventil
patient
present
sever
respiratori
ill
hospit
within
median
day
onset
symptom
requir
icu
admiss
within
hour
hospit
admiss
comparison
caus
viral
pneumon
season
influenza
increas
number
patient
gastrointestin
symptom
typic
diarrhea
common
radiolog
find
bilater
patchi
consolid
andor
groundglass
opac
often
wors
lower
lung
zone
fig
among
requir
icu
admiss
ventil
least
lung
quadrant
cxr
commonli
involv
comput
tomographi
scan
chest
show
similar
find
predominantli
diffus
groundglass
infiltr
consolid
canada
icu
patient
pneumon
mean
pao
fraction
inspir
oxygen
fio
admiss
mm
hg
remain
averag
lower
among
remain
icu
day
seventythre
percent
patient
ali
onset
critic
ill
addit
oxygen
ventilatori
support
measur
infrequ
use
includ
highfrequ
oscillatori
ventil
nitric
oxid
neuromuscular
blockad
prone
ventil
extracorpor
membran
oxygen
similar
degre
influenza
viral
pneumonia
sever
hypoxemia
note
multipl
case
seri
countri
thorac
complianc
note
decreas
subset
patient
hypoxem
respiratori
failur
median
mlcm
h
interquartil
rang
mlcm
h
signific
number
patient
develop
least
organ
dysfunct
case
develop
multisystem
organ
dysfunct
durat
ventil
vari
averag
median
mean
report
day
common
caus
death
sever
ard
refractori
hypoxemia
complic
relat
includ
infect
sepsi
multisystem
organ
dysfunct
common
infecti
complic
secondari
bacteri
pneumonia
frequent
attribut
aureu
pneumonia
diagnosi
pneumon
made
base
compat
clinic
syndrom
alreadi
describ
detect
influenza
viru
rtpcr
andor
viral
cultur
viral
cultur
take
week
process
thu
rtpcr
typic
nasopharyng
swab
prefer
techniqu
pandem
note
falseneg
nasopharyng
aspir
occur
patient
viral
pneumon
sever
case
ill
tracheal
aspir
bronchoalveolar
lavag
specimen
intub
patient
repeat
collect
recommend
increas
pcr
diagnost
yield
pathophysiolog
whether
ard
secondari
relat
direct
damag
viru
host
immun
respons
viru
unclear
pandem
viru
replic
upper
lower
respiratori
tract
comparison
season
influenza
predominantli
replic
upper
respiratori
tract
retrospect
studi
hong
kong
colleagu
examin
pattern
clinic
diseas
viral
load
immunolog
profil
patient
vari
sever
die
ard
delay
clearanc
viral
load
nasopharynx
higher
level
proinflammatori
cytokin
chemokin
higher
likelihood
viremia
signific
correl
level
interleukin
diseas
sever
associ
high
sever
diseas
influenza
previous
establish
initi
nasopharyng
endotrach
viral
load
similar
among
patient
differ
diseas
sever
therefor
would
appear
viral
load
onset
infect
determin
diseas
sever
patient
die
multisystem
organ
failur
follow
admiss
sever
ard
macroscop
examin
lung
note
heavi
diffus
edemat
area
consolid
hemorrhag
lung
patholog
typic
show
diffus
alveolar
damag
dad
time
associ
area
hemorrhag
necrot
bronchiol
fig
report
center
diseas
control
prevent
cdc
frequent
histopatholog
airway
patient
inflamm
edema
less
frequent
necrosi
epithelium
hemorrhag
lung
tissu
case
show
variou
stage
dad
includ
edema
hyalin
membran
inflamm
fibrosi
seventeen
patient
pulmonari
thromboemboli
immunohistochemistri
show
viral
antigen
airway
epitheli
cell
submucos
gland
pneumocyt
viral
antigen
also
commonli
seen
alveolar
macrophag
studi
show
viru
abil
target
lower
upper
respiratori
tract
infect
thu
lead
dad
clinic
ard
overal
patholog
find
fairli
similar
publish
autopsi
studi
prior
influenza
epidem
includ
evid
superimpos
bacteri
pneumonia
sever
studi
examin
risk
factor
develop
ard
relat
note
time
treatment
antivir
import
patient
receiv
appropri
antivir
therapi
oseltamivir
zanamavir
shortli
present
medic
care
better
outcom
rapid
initi
antivir
infect
suspect
particularli
import
risk
factor
diseas
progress
requir
hospit
ideal
therapi
start
within
hour
symptom
onset
also
effect
recommend
given
later
recommend
dose
mg
twice
day
although
higher
dose
given
center
critic
ill
obes
patient
accord
recommend
recent
data
suggest
mg
oseltamivir
administ
twice
per
day
via
orogastr
rout
critic
ill
patient
consist
yield
suffici
blood
level
near
maxim
vitro
suppress
viral
replic
patient
also
receiv
broadspectrum
antimicrobi
therapi
least
initi
investig
pend
determin
caus
respiratori
failur
current
recommend
cdc
state
antivir
treatment
recommend
earli
possibl
patient
confirm
suspect
influenza
requir
hospit
sever
complic
progress
ill
high
risk
influenza
complic
ie
year
year
immunocompromis
chronic
diseas
pregnant
postpartum
morbidli
obes
aborigin
resid
nurs
home
longterm
care
facil
current
recommend
therapi
either
oseltamivir
inhal
zanamivir
howev
individu
underli
respiratori
diseas
oseltamivir
recommend
zanamivir
critic
ill
patient
pneumonia
viral
rna
may
detect
lower
airway
secret
sever
week
initi
oseltamivir
patient
influenza
pneumonia
evid
clinic
progress
increas
dose
oseltamivir
mg
twice
daili
adult
importantli
increas
durat
therapi
day
instead
day
may
warrant
oseltamivirresist
virus
isol
common
resist
via
mutat
viral
neuraminidas
confer
highlevel
resist
oseltamivir
zanamivir
resist
isol
found
patient
prior
oseltamivir
exposur
associ
mild
selflimit
diseas
oseltamivir
resist
suspect
confirm
treatment
zanamivir
patient
admit
icu
viral
pneumon
fulfil
criteria
ali
ard
requir
mechan
ventil
mani
patient
initi
noninvas
positivepressur
ventil
nippv
fail
mode
subsequ
requir
intub
invas
ventil
report
success
use
nippv
like
relat
select
less
hypoxem
patient
mode
treatment
concern
aros
regard
transmiss
nippv
mode
ventil
gener
respiratori
droplet
aerosol
reach
radiu
surround
patient
receiv
nippv
center
intern
ventil
viral
pneumon
patient
low
tidal
ventil
mlkg
predict
bodi
weight
plateau
pressur
cm
h
whenev
possibl
recommend
ard
base
result
ardsnet
trial
high
level
posit
endexpiratori
pressur
peep
note
requir
manag
sever
hypoxemia
mean
peep
level
cm
h
report
studi
mode
ventil
also
use
includ
airway
pressur
releas
ventil
highfrequ
oscil
howev
insuffici
data
conclus
state
whether
mode
impact
outcom
similarli
recruit
maneuv
prone
posit
inhal
nitric
oxid
use
salvag
therapi
refractori
hypoxemia
insuffici
evid
determin
effect
sever
studi
report
use
extracorpor
membran
oxygen
ecmo
pandem
largest
seri
australia
patient
sever
ard
median
pao
fio
peep
cm
h
initi
ecmo
seventyon
percent
surviv
icu
admiss
die
comparison
patient
treat
ecmo
ard
previou
year
australian
center
report
countri
use
ecmo
ard
relat
pneumonia
much
smaller
mortal
rate
avoid
volum
overload
judici
diuresi
may
also
associ
reduc
durat
ventil
length
stay
icu
patient
ard
strategi
use
recommend
patient
ard
relat
steroid
use
variabl
number
patient
across
studi
vari
indic
sepsi
copd
asthma
exacerb
stressdos
replac
therapi
ard
one
studi
argentina
examin
effect
treatment
corticosteroid
found
steroid
safe
associ
improv
lung
injuri
score
howev
patient
real
compar
group
patient
receiv
degre
steroid
therapi
studi
european
societi
intens
care
medicin
registri
found
earli
use
corticosteroid
patient
admit
icu
associ
increas
risk
superinfect
predominantli
hospitalacquir
pneumonia
mortal
benefit
similarli
studi
found
mortal
benefit
even
harm
earli
steroid
use
present
insuffici
evid
routin
use
steroid
influenzarel
ard
histor
data
experi
recent
influenza
epidem
suggest
potenti
util
convalesc
serum
manag
sever
influenza
although
research
issu
clearli
requir
use
convalesc
serum
immunoglobulin
may
becom
use
treatment
modal
futur
pandem
influenza
virus
resist
current
antivir
agent
adenoviru
common
caus
mild
upper
respiratori
ill
children
howev
children
infect
adenoviru
develop
pneumonia
among
adult
adenoviru
account
respiratori
infect
particularli
among
immunocompromis
adult
close
crow
set
endem
case
occur
throughout
year
addit
epidem
report
among
militari
recruit
longterm
care
facil
hospit
rapid
spread
influenza
viral
pneumonia
viru
adenoviru
also
shown
caus
potenti
fatal
pneumonia
predominantli
immunocompromis
host
especi
transplant
recipi
symptomatolog
similar
viral
pneumonia
fever
cough
preced
upper
respiratori
symptom
bilater
interstiti
infiltr
cxr
case
sever
adenovir
pneumonia
casefat
rate
high
may
case
adenovir
pneumonia
due
serotyp
transmiss
occur
via
respiratori
droplet
secret
tear
fecalor
spread
environment
surfac
infectioncontrol
measur
paramount
limit
diseas
spread
incub
period
rang
day
infect
respiratori
tract
also
associ
gastrointestin
symptom
gastroenter
diarrhea
detect
viru
pcr
serolog
test
viral
cultur
pcr
highest
sensit
specif
wherea
viral
cultur
insensit
take
day
treatment
adenoviru
infect
support
mild
diseas
approv
antivir
drug
although
often
use
sever
case
ribavirin
guanosin
analogu
shown
effect
small
clinic
studi
immunocompromis
patient
sever
diseas
cidofovir
cytosin
nucleotid
analogu
inhibit
dna
polymeras
greatest
activ
viru
prefer
agent
sever
nonrandom
studi
hematopoiet
stem
cell
transplant
recipi
shown
favor
respons
agent
combin
therapi
cidofovir
pool
intraven
immunoglobulin
ivig
use
data
efficaci
therapi
lack
sever
acut
respiratori
syndrom
sar
coronaviru
first
discov
epidem
origin
southern
china
spread
rapidli
limit
number
case
rest
asia
europ
canada
unit
state
sar
highli
contagi
viru
high
rate
spread
identifi
health
care
worker
casefat
rate
epidem
strongli
associ
increas
age
casefat
rate
older
year
sar
note
multipl
mode
transmiss
includ
droplet
airborn
spread
well
direct
contact
contamin
surfac
nosocomi
case
contamin
surfac
includ
surfac
patient
room
clinic
present
sar
one
prolong
influenzalik
prodrom
fever
cough
chill
myalgia
dyspnea
headach
infect
progress
respiratori
symptom
profound
patient
requir
icu
admiss
mechan
ventil
median
day
symptom
onset
common
radiograph
present
focal
unilater
peripher
airspac
diseas
progress
multifoc
unilater
bilater
diseas
diagnosi
made
base
clinic
suspicion
contact
known
case
confirm
either
serolog
test
rtpcr
rtpcr
sar
limit
sensit
specif
therefor
repeat
sampl
recommend
influenza
tracheal
aspir
may
help
intub
patient
sever
pneumonia
serolog
test
sensit
test
take
sever
week
antibodi
develop
mean
time
seroconvers
approxim
day
treatment
sar
support
littl
evid
effect
antivir
pharmacolog
therapi
novel
coronaviru
discov
septemb
refer
middl
east
respiratori
syndrom
mer
coronaviru
may
case
confirm
death
rate
case
occur
within
arab
peninsula
neighbor
countri
infect
novel
coronaviru
led
sever
lower
respiratori
tract
ill
low
rate
humantohuman
transmiss
howev
concern
arisen
viru
may
adapt
effici
transmiss
rsv
envelop
rna
viru
paramyxoviru
famili
primarili
associ
fall
winter
epidem
lower
respiratori
ill
infant
young
children
newborn
infect
first
winter
rsv
infect
adult
gener
repres
reinfect
may
etiolog
agent
communityacquir
lower
respiratori
tract
infect
among
elderli
rsv
infect
common
may
account
winter
hospit
admiss
casefat
rate
similar
influenza
risk
factor
sever
diseas
advanc
age
immunocompromis
state
chronic
cardiopulmonari
diseas
higher
death
rate
report
rsv
lower
respiratori
tract
infect
adult
present
wheez
ill
case
along
crackl
pneumon
infiltr
howev
classic
bronchiol
pictur
seen
infant
rare
adult
popul
adult
present
nasal
congest
cough
lowgrad
fever
follow
dyspnea
wheez
often
adult
clinic
featur
difficult
distinguish
respiratori
virus
howev
myalgia
fever
less
common
wheez
rhinorrhea
common
rsv
influenza
infect
cxr
often
demonstr
small
focal
infiltr
lobar
infiltr
describ
diagnosi
best
made
rtpcr
nasal
aspir
avail
lower
respiratori
sampl
bronchoalveolar
lavag
deep
tracheal
suction
viral
cultur
less
sensit
aerosol
form
ribavirin
approv
treatment
rsv
children
data
adult
popul
limit
ribavirin
use
immunocompromis
adult
upper
lower
respiratori
tract
infect
either
alon
combin
ivig
standard
rsvivig
spread
via
larg
droplet
fomit
isol
cohort
infect
patient
recommend
human
metapneumoviru
hmpv
close
relat
rsv
primari
infect
often
occur
childhood
howev
rsv
immun
incomplet
children
clinic
manifest
similar
rsv
incid
symptomat
infect
adult
gener
less
studi
prospect
studi
hospit
adult
cardiorespiratori
ill
winter
season
hmpv
identifi
cohort
patient
requir
icu
admiss
ventilatori
support
respect
mortal
rate
overal
coinfect
rsv
coronaviru
influenza
note
hmpv
result
pneumonia
respiratori
failur
although
less
common
influenza
rsv
clinic
symptom
indistinguish
respiratori
virus
risk
factor
sever
diseas
also
similar
virus
includ
older
age
immunocompromis
state
chronic
cardiorespiratori
diseas
cxr
reveal
patchi
infiltr
predominantli
lower
lung
zone
identif
viru
optim
involv
rtpcr
direct
immunofluoresc
hmpv
replic
slowli
grow
ineffici
use
tradit
viral
cultur
method
mainstay
treatment
viral
infect
support
case
report
seri
report
ribavirin
potenti
effect
treatment
although
studi
need
recommend
virus
import
caus
communityacquir
pneumonia
pediatr
adult
popul
viral
pneumonia
tend
season
predilect
often
preced
prodrom
ill
diseas
surveil
system
import
detect
outbreak
particularli
emerg
novel
viral
pathogen
capabl
human
transmiss
sever
common
viral
pathogen
lead
sever
respiratori
diseas
includ
common
viru
influenza
unfortun
appropri
diagnost
test
often
pursu
unavail
particularli
smaller
commun
hospit
treatment
viral
pneumonia
gener
support
howev
diagnost
test
isol
caus
viru
import
pathogen
influenza
viru
effect
antivir
therapi
specif
case
earli
treatment
antivir
therapi
appear
associ
improv
outcom
